The M184V mutation reduces the selective excision of zidovudine 5′-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1

Journal of Virology

Volumn 76, Issue 7, 2002, Pages 3248-3256

  Boyer, Paul L ^a   Sarafianos, Stefan G ^a   Arnold, Edward ^a   Hughes, Stephen H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE 5' PHOSPHATE; ZIDOVUDINE 5' TRIPHOSPHATE;

ARTICLE; COMPLEX FORMATION; CROSS RESISTANCE; DRUG HYPERSENSITIVITY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; EXCISION REPAIR; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; OPEN READING FRAME; POLYMERIZATION; PRIORITY JOURNAL; SENSITIZATION; TARGET CELL; VIRUS MUTATION;

ADENOSINE TRIPHOSPHATE; DRUG RESISTANCE, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; THYMINE NUCLEOTIDES; ZIDOVUDINE;

EID: 0036124432     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.7.3248-3256.2002     Document Type: Article

References (26)

1. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): Increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase
2. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme
3. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy
4. High level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase
5. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1
6. YADD mutants of human immunodeficiency virus type 1 and Moloney murine leukemia virus reverse transcriptase are resistant to lamivudine triphosphate (3TCTP) in vitro
7. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase
8. Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reverse transcriptase inhibitors
9. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication
10. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis
11. Structure of a covalently trapped catalytic complex of HIV-1 RT: Implications for drug resistance
12. 3′-azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors
13. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase
14. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
15. Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants
16. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism
17. A mechanism of AZT resistance: An increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase
18. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2′-deoxynucleoside triphosphates
19. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: Analysis of enzyme processivity, chain-terminator removal, and viral replication
20. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
21. 3TC (lamivudine) resistance in HIV-1 reverse transcriptase involves steric hindrance with β-branched amino acids
22. Mutations in retroviral genes associated with drug resistance: 2000-2001 Update
23. Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs)
24. Zidovudine/lamivudine co-resistance is preceded by a transient period of zidovudine hypersensitivity
25. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
26. Nucleotide-induced stable complex formation by HIV-1 reverse transcriptase